Press Releases


Therapeutic Solutions International Continues to Refine NanoStilbene™ Formulation

NanoStilbene Shown to Reduce Tumor Necrosis Factor-α (TNF-α )in Cancer Patients

OCEANSIDE, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Therapeutics Solutions International, Inc., (USOTC: TSOI) announced today further refinement of their patented formulation of nanoparticle pterostilbene known as NanoStilbene™.

NanoStilbene™ is a nanoemulsion of nanoparticle pterostilbene in the 75-90nm (nanometer) range at a concentration of 200mg per milliliter. We have successfully produced the same stable nanoemulsion using peach kernel extract to fortify the NanoStilbene against tumor necrosis factor-α (TNF-α ).

“We recently announced the conclusion of a clinical trial involving 12 advanced, solid tumor, cancer patients who received the equivalence of 300mg’s of nanoparticle pterostilbene daily for three weeks which showed on average a 26% decrease in TNF-α 1,” said Tim G Dixon CEO & President of Therapeutic Solutions International, Inc. “By adding peach kernel extract to our nanoemulsion formulation we intend to fortify NanoStilbene to be even more effective against high levels of inflammatory cytokines.”

“In a recent paper, peach kernel extract has been shown to reduce tissue factor (TF) elevations in atherosclerosis, which is a pathological process in arteries due to plaque formation, by first reducing tumor necrosis factor-α (TNF-α)2,” said Dr. Thomas Ichim, Director of Therapeutic Solutions International. “Tumor necrosis factor (TNF) is a type of messenger protein known as a cytokine that is produced by white blood cells. It promotes inflammation, produces other cells used in the inflammatory response, and can help cells heal” added Dr. Ichim.

“By adding the peach kernel extract to the nanoemulsion formulation, our purpose is to open the way for new therapeutic approaches that might eventually decrease the prevalence of tumor necrosis factor-α (TNF-α) in not only cancer patients where TNF-α has been shown to play a key role in these inflammatory processes but also in acute and chronic inflammatory conditions such as trauma, sepsis, infection, rheumatoid arthritis, atherosclerosis, and cardiovascular disease” said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International.

TNF-α is a member of a growing family of peptide mediators comprising at least 19 cytokines, including lymphotoxin-, Fas ligand, and CD40 ligand. TNF-α has important proinflammatory properties, which play crucial roles in the innate and adaptive immunity, cell proliferation, and apoptotic processes. The cytokine is produced by different kind of cells, including macrophages, monocytes, T-cells, smooth muscle cells, adipocytes, and fibroblasts.

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. The Company’s corporate website is at and our e-commerce is at and for additional info on NanoStilbene visit

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Contact Information:

Therapeutic Solutions International, Inc.